Global Fibromyalgia Pipeline Review, H2 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 22, 2019--
The “Fibromyalgia - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report provides an overview of the Fibromyalgia (Central Nervous System) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Fibromyalgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Fibromyalgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia (Fibromyalgia Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 6, 4, 1 and 6 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.
Fibromyalgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Fibromyalgia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Fibromyalgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fibromyalgia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fibromyalgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fibromyalgia (Central Nervous System).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fibromyalgia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fibromyalgia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Featured News & Press Releases
- Oct 28, 2019: Aptinyx announces results of phase 2 fibromyalgia study of NYX-2925 have been selected for late-breaking presentation at the American College of Rheumatology Annual Meeting
- Oct 03, 2019: Tonix Pharmaceuticals announces completion of long-term exposure studies in participants with PTSD to evaluate the Tolerability of TNX-102 SL 5.6 mg
- Aptinyx Inc
- Astellas Pharma Inc
- Grunenthal GmbH
- H. Lundbeck AS
- Innovative Med Concepts LLC
- Intec Pharma Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Luye Pharma Group Ltd
- Tetra Bio-Pharma Inc
- Teva Pharmaceutical Industries Ltd
- Tonix Pharmaceuticals Holding Corp
- Vitality Biopharma Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8w6h27
View source version on businesswire.com:https://www.businesswire.com/news/home/20191122005354/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 11/22/2019 10:14 AM/DISC: 11/22/2019 10:14 AM